⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NXL News
Nexalin Technology, Inc. Common Stock
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
globenewswire.com
NXL
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
globenewswire.com
NXL
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
accessnewswire.com
NXL
BIVI
BIVI